CD20 Antibodies

Santa Cruz Biotechnology features a diverse variety of CD20 monoclonal antibodies for research in understanding B-cell biology and related diseases. CD20 monoclonal antibodies are validated for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). CD20 is a transmembrane protein expressed on the surface of B-cells and plays a crucial role in B-cell activation, proliferation, and differentiation. CD20 serves as a significant target in the treatment of B-cell malignancies, such as non-Hodgkin lymphoma and chronic lymphocytic leukemia, making CD20 monoclonal antibodies essential tools for both basic research and therapeutic applications. Understanding CD20 function can provide insights into immune responses and the development of targeted therapies. Researchers worldwide rely on CD20 monoclonal antibodies to advance their understanding of B-cell development and function. CD20 monoclonal antibodies enable detailed investigation of B-cell markers and their roles in health and disease. Santa Cruz Biotechnology monoclonal antibodies support researchers in making meaningful contributions to immunology and oncology research.